ARCC-4 is a potent Androgen Receptor (AR) degrader utilizing the PROTAC mechanism. It functions as an enzalutamide-based von Hippel-Lindau (VHL)-recruiting AR PROTAC and effectively degrades clinically significant AR mutants linked to antiandrogen therapy.
Usually ships within 24 hours.